About Flame Biosciences
Flame Biosciences is a company based in New York (United States) founded in 2019 by Charles J Fisher and Bob Stein. Flame Biosciences has raised $108.52 million across 2 funding rounds. Flame Biosciences operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter New York, United States
- Founders Charles J Fisher, Bob Stein
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$108.52 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series B
Sep 30, 2020
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Flame Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Flame Biosciences
Flame Biosciences has successfully raised a total of $108.52M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Flame Biosciences
Investment portfolio details for Flame Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Flame Biosciences
Detailed financials for Flame Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Flame Biosciences Comparisons
Peer comparison for Flame Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Flame Biosciences
Flame Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for allergic and inflammatory diseases are developed.
|
Detailed competitors of Flame Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Flame Biosciences
Complete news archive for Flame Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Flame Biosciences
Flame Biosciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Flame Biosciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Harlan Weisman is the current CEO of Flame Biosciences.
Flame Biosciences is a funded company, having raised a total of $108.52M across 2 funding rounds to date.
Flame Biosciences was founded in 2019 and is based in New York, United States. Operations center on the biotechnology sector, where drugs targeting cancer and inflammatory conditions are developed and manufactured. The pipeline addresses chronic inflammation-related issues, including lung cancers and chronic kidney disease. FL-101 is pursued for treating inflammation-associated lung cancers, while FL-201 is designed to alleviate chronic inflammation in patients with severe conditions.
Flame Biosciences's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.